Why GLP-1 Agonists May Not Be Safe for People with Type 1 Diabetes Eric Han Feb 23 4 min read GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza), and tirzepatide (Mounjaro, Zepbound) have dramatically improved treatment options for Type 2 diabetes and obesity
3rd party Lab Tested in the USA : We have our own FDA registered Food-Grade facility in the USA
Originally created to manage blood sugar in type 2 diabetes, its now widely used for weight management
Thats why we: Start low and increase slowly Check in regularly Adjust based on your body , not just a schedule When done right, GLP-1 medications work with your bodynot against it
When HIF-1 is not hydroxylated, and is thus not targeted for degradation by ubiquitylation, it migrates to the nucleus leading to an increase in the transcription of HIF-1 target genes